

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康灃生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

VOLUNTARY ANNOUNCEMENT

BREAKTHROUGH MEDICAL DEVICE DESIGNATION GRANTED BY FDA FOR ASTHMA CRYOABLATION SYSTEM

This announcement is made by Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders of the Company and potential investors about the latest business development of the Group.

The Company is pleased to announce that on July 24, 2025, the Group’s Asthma Cryoablation System (the “**Asthma Cryoablation System**”), which is one of the Group’s respiratory intervention products and consists of a cryotherapy equipment and an airway cryoablation catheter, was granted Breakthrough Medical Device Designation by the U.S. Food and Drug Administration (the “**FDA**”).

The Asthma Cryoablation System is a self-developed cryoablation system indicated to treat moderate and severe asthma. During the procedure, the Asthma Cryoablation System destroys the vagus nerve in the lungs through cryoablation, reducing the release of over-activated acetylcholine that is a cause of asthma, and decreasing mucus secretion, thus achieving the effect of treating asthma.

THE COMPANY CANNOT GUARANTEE THE FUTURE PROSPECTS OF THE ASTHMA CRYOABLATION SYSTEM. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, July 24, 2025

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.